Pharmacokinetics and excretion of phenolic acids from mailuoning injection in rats

Abstract

Abstract: AIM: To study the pharmacokinetics of phenolic acids from Mailuoning injection in rats. METHODS: SD rats were given a single i.v.administration dose of Mailuoning injection 10 mL/kg, plasma and urine were collected before and after injection. Phenolic acid components in plasma and urine were measured by LC MS.Pharmacokinetic parameters were determined from the plasma concentration-time data and urinary excretion-time data with the DAS software package.RESULTS: After i.v.of Mailuoning injection, chlorogenic acid (CGA), 1, 5-dicaffeylquinic acid (1, 5-DCQA), 3, 4-dicaffeylquinic acid (3, 4-DCQA), 3, 5-dicaffeylquinic acid (3, 5-DCQA)and caffeic acid (CA)were quickly excrectioned.The t_1/2 of CGA, 1, 5-DCQA, 3, 4-DCQA, 3, 5-DCQA and CA were 0.649, 0.334, 0.479, 0.486 and 0.330 h, respectively.AUC_0-∞ were (22.522±2.716), (0.353±0.062), (3.620±1.246), (5.287±1.627)and (2.257±0.360)mg·L^-1 ·h, respectively.After i.v. of Mailuoning injection, CGA, 1, 5-DCQA, 3, 4-DCQA, 3, 5-DCQA and CA can all be detected in the urine.The amounts of CGA, 1, 5-DCQA, 3, 4-DCQA, 3, 5-DCQA and CA excreted from urine during 0-24 h were (122.22±26.49)%, (3.30±1.26)%, (0.24±0.11)%, (1.93± 0.77)% and (18.61± 4.99)% of dose given in rats, respectively.CONCLUSION: After i.v.of Mailuoning injection, phenolic acids can be excreted quickly.Only a small quantity of 1, 5-DCQA, 3, 4-DCQA, 3, 5-DCQA and CA were excreted from urine.3, 4-DCQA and 3, 5-DCQA may be metabolized into CGA in the rat plasma.

Key words: phenolic acids, Mailuoning injection, pharmacokinetics, LC/MS

CLC Number:

WANG Wei, WANG Guang-ji, HAO Hai-ping, CUI Nan, SUN Xuan-rong. Pharmacokinetics and excretion of phenolic acids from mailuoning injection in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 776-781.

References

[1] Heo HJ, Kim YJ, Chung D, et al. Antioxidant capacities of individual and combined phenolics in a model sy stem [J]. Food Chem, 2007, 104(1): 87-92.
[2] Pietraforte D, Castelli M, Metere A, et al. Salivary uric acid at the acidic pH of the stomach is the principal defense against nitrite-derived reactive species: sparing effects of chlorogenic acid and serum albumin[J]. Free Radic Biol Med, 2006, 41(12): 1753-1763.
[3] Szaefer H, Kaczmarek J, Rybczy′nska M, et al. The effect of plant phenols on the expression and activity of phorbol ester-induced PKC in mouse epidermis[J]. Toxicol, 2007, 230(1): 1-10.
[4] Nakajima Y, Shimazawa M, Mishima S, et al. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions[J]. Life Sci, 2007, 80(4): 370-377.
[5] Schindler PW, Below P, Hemmerle H, et al. Identification of two new inhibitors of the hepatic glucose-6-phosphatase system[J]. Drug Dev Res, 1998, 44: 34-40.
[6] Zhang QL, Li J, Wang C, et al. A gradient HPLC method for the quality control of chlorogenic acid, linarin and luteolin in Flos Chrysanthemi Indici suppository [J]. J Pharm Biomed Anal, 2007, 43(2): 753-757.
[7] Yuan XD, Koh HL, Chui WK. A high performance liquid chromatography method for the simultaneous determination of arctiin, chlorogenic acid and glycyrrhizin in a Chinese proprietary medicine[J]. J Pharm Biomed Anal, 2005, 39 (3/4): 697-704.
[8] She ZY, Ke X, Ping QN. Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats [J]. Chin J Nat Med, 2007, 5(1): 50-55.
[9] Wang SJ, Zhang ZQ, Zhao YH, et al. Simultaneous quantification of chlorogenic acid and caffeic acid in rat plasma after an intravenous administration of mailuoning injection using liquid chromatography mass spectrometry [J]. Rapid CommunMass Spectrom, 2006, 20(15): 2303-2308.
[10] Yang B, Meng ZY, Dong JX, et al. Metabolic profile of 1, 5-dicaffeoylquinic acid in rats, an in vivo and in vitro study[J]. Drug Metab Dispos, 2005, 33(7): 930-936.
[11] Moridani MY, Scobie H, Jamshidzadeh A, et al. Caffeic acid, chlorogenic acid, and dihydrocaffeic acid metabolism: glutathione conjugate formation[J]. Drug Metab Dispos, 2001, 29(11): 1432-1439.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.